Recurrent prostate cancer: combined role for MRI and PSMA-PET in
Magnetic resonance imaging
Positron-emission tomography
Prostate cancer
Tumor staging
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
23
08
2023
accepted:
10
10
2023
revised:
07
10
2023
medline:
1
12
2023
pubmed:
1
12
2023
entrez:
1
12
2023
Statut:
aheadofprint
Résumé
To investigate the specific strengths of MRI and PET components in Patients with biochemical recurrence of PCa and contrast-enhanced whole-body Altogether 102 patients (mean aged 68 ± 8 years, median PSA 1.33 ng/mL) were included. PCa was found in 70/102 (68%) patients. Accuracy of MRI in the detection of Tr, N1, M + , M1a, and M1b was 100%, 79%, 90%, 97%, and 95% for PSA < 1.69 ng/mL and 100%, 87%, 87%, 91%, and 96% for PSA > 1.69 ng/mL. Accuracy of Combined assessment of This study gives a scientific baseline to improve the understanding and reading of • Combining the individual modality strengths of
Identifiants
pubmed: 38038758
doi: 10.1007/s00330-023-10442-4
pii: 10.1007/s00330-023-10442-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
EAU Guidelines Office. EAU-Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022. ISBN 978–94–92671–16–5.
Suardi N, Porter CR, Reuther AM et al (2008) A nomogram predicting long-term biochemical recurrence after radical prostatectomy. Cancer 112:1254–1263
doi: 10.1002/cncr.23293
pubmed: 18286530
Chun FKH, Graefen M, Zacharias M et al (2006) Anatomic radical retropubic prostatectomy—long-term recurrence-free survival rates for localized prostate cancer. World J Urol 24:273–280
doi: 10.1007/s00345-006-0058-2
pubmed: 16506049
Cookson MS, Aus G, Burnett AL et al (2007) Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177:540–545
doi: 10.1016/j.juro.2006.10.097
pubmed: 17222629
De Visschere PJL, Standaert C, Fütterer JJ et al (2019) A systematic review on the role of imaging in early recurrent prostate cancer. Eur Urol Oncol 2:47–76
doi: 10.1016/j.euo.2018.09.010
pubmed: 30929846
Ekmekcioglu Ö, Busstra M, Klass ND, Verzijlbergen F (2019) Bridging the imaging gap: PSMA PET/CT has a high impact on treatment planning in prostate cancer patients with biochemical recurrence—a narrative review of the literature. J Nucl Med 60:1394–1398
doi: 10.2967/jnumed.118.222885
pubmed: 30850500
Fendler WP, Calais J, Eiber M et al (2019) Assessment of 68Ga-PSMA-11 PET accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol 5:856–863
doi: 10.1001/jamaoncol.2019.0096
pubmed: 30920593
pmcid: 6567829
Fendler WP, Eiber M, Beheshti M et al (2023) PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50(5):1466–1486. https://doi.org/10.1007/s00259-022-06089-w
Hope TA, Eiber M, Armstrong WR et al (2021) Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol 7:1635–1642
doi: 10.1001/jamaoncol.2021.3771
pubmed: 34529005
pmcid: 8446902
Freitag MT, Radtke JP, Afshar-Oromieh A et al (2017) Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging 44:776–787
doi: 10.1007/s00259-016-3594-z
pubmed: 27988802
Achard V, Lamanna G, Denis A et al (2019) Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI. Med Oncol 36:67
doi: 10.1007/s12032-019-1291-z
pubmed: 31190232
Wieder H, Beer A, Holzapfel K et al (2017) 11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer. Oncotarget 8:66516–66527
doi: 10.18632/oncotarget.16227
pubmed: 29029532
pmcid: 5630432
Barchetti F, Stagnitti A, Megna V et al (2016) Unenhanced whole-body MRI versus PET-CT for the detection of prostate cancer metastases after primary treatment. Eur Rev Med Pharmacol Sci 20:3770–3776
pubmed: 27735042
Schwenzer NF, Pfannenberg C, Reischl G, Werner MK, Schmidt H (2012) Einsatz von MR/PET in der onkologischen Bildgebung. Rofo 184:780–787
doi: 10.1055/s-0031-1299334
pubmed: 22618473
Zhang-Yin J, Montravers F, Montagne S, Hennequin C, Renard-Penna R (2022) Diagnosis of early biochemical recurrence after radical prostatectomy or radiation therapy in patients with prostate cancer: state of the art. Diagn Interv Imaging 103:191–199
doi: 10.1016/j.diii.2022.02.005
pubmed: 35227633
Evangelista L, Zattoni F, Cassarino G et al (2021) PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 48:859–873
doi: 10.1007/s00259-020-05025-0
pubmed: 32901351
World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V (2020) Prostate Imaging Quality (PI-QUAL): a new quality control scoring system for multiparametric magnetic resonance imaging of the prostate from the PRECISION trial. Eur Urol Oncol 3:615–619
doi: 10.1016/j.euo.2020.06.007
pubmed: 32646850
Kirchner J, O’Donoghue JA, Becker AS, Ulaner GA (2021) Improved image reconstruction of 89Zr-immunoPET studies using a Bayesian penalized likelihood reconstruction algorithm. EJNMMI Physics 8:6
doi: 10.1186/s40658-021-00352-z
pubmed: 33469848
pmcid: 7815860
Jannusch K, Lindemann ME, Bruckmann NM et al (2023) Towards a fast PET/MRI protocol for breastcancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times. Eur Radiol 33(9):6179–6188. https://doi.org/10.1007/s00330-023-09580-6
doi: 10.1007/s00330-023-09580-6
pubmed: 37045980
pmcid: 10415438
Eiber M, Herrmann K, Calais J et al (2018) Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med 59:469–478
doi: 10.2967/jnumed.117.198119
pubmed: 29123012
Valentin B, Arsov C, Ullrich T et al (2022) Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer. Eur J Radiol 147:110110
doi: 10.1016/j.ejrad.2021.110110
pubmed: 34952329
Beiderwellen K, Grueneisen J, Ruhlmann V et al (2015) [18F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results. Eur J Nucl Med Mol Imaging 42:56–65
doi: 10.1007/s00259-014-2902-8
pubmed: 25223420
Kirchner J, Deuschl C, Schweiger B et al (2017) Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. Eur J Nucl Med Mol Imaging 44:1742–1750
doi: 10.1007/s00259-017-3726-0
pubmed: 28534182
Sawicki LM, Grueneisen J, Schaarschmidt BM et al (2016) Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol 85:459–465
doi: 10.1016/j.ejrad.2015.12.010
pubmed: 26781152
Buchbender C, Hartung-Knemeyer V, Beiderwellen K et al (2013) Diffusion-weighted imaging as part of hybrid PET/MRI protocols for whole-body cancer staging: does it benefit lesion detection? Eur J Radiol 82:877–882
doi: 10.1016/j.ejrad.2013.01.019
pubmed: 23428414
Cornford P, van den Bergh RC, Briers E et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79:263–282
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33039206
Panebianco V, Barchetti F, Musio D et al (2014) Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy. Biomed Res Int 2014:827265
doi: 10.1155/2014/827265
pubmed: 24757679
pmcid: 3971570
Radzina M, Tirane M, Roznere L et al (2020) Accuracy of (68)Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer. Am J Nucl Med Mol Imaging 10:106–118
pubmed: 32419979
pmcid: 7218697
Glemser PA, Rotkopf LT, Ziener CH et al (2022) Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer. Cancer Imaging 22:53
doi: 10.1186/s40644-022-00489-9
pubmed: 36138437
pmcid: 9502876
Giesel FL, Hadaschik B, Cardinale J et al (2017) F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 44:678–688
doi: 10.1007/s00259-016-3573-4
pubmed: 27889802
Schilham MGM, Zamecnik P, Privé BM et al (2021) Head-to-head comparison of 68Ga-prostate-specific membrane antigen PET/CT and ferumoxtran-10–enhanced MRI for the diagnosis of lymph node metastases in prostate cancer patients. J Nucl Med 62:1258–1263
doi: 10.2967/jnumed.120.258541
pubmed: 33517328
pmcid: 8882902
Hövels AM, Heesakkers RAM, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387–395
doi: 10.1016/j.crad.2007.05.022
pubmed: 18325358
Freitag MT, Radtke JP, Hadaschik BA et al (2016) Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging 43:70–83
doi: 10.1007/s00259-015-3206-3
pubmed: 26508290
Rajarubendra N, Bolton D, Lawrentschuk N (2010) Diagnosis of Bone Metastases in Urological Malignancies—An Update. Urology 76:782–790
doi: 10.1016/j.urology.2009.12.050
pubmed: 20346492
Zacho HD, Nielsen JB, Afshar-Oromieh A et al (2018) Prospective comparison of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging 45:1884–1897
doi: 10.1007/s00259-018-4058-4
pubmed: 29876619
de Galiza Barbosa F, Queiroz MA, Nunes RF, Marin JFG, Buchpiguel CA, Cerri GG (2018) Clinical perspectives of PSMA PET/MRI for prostate cancer. Clinics (Sao Paulo) 73(suppl 1):e586s. https://doi.org/10.6061/clinics/2018/e586s
doi: 10.6061/clinics/2018/e586s
pubmed: 30281701
Sonni I, Felker ER, Lenis AT et al (2022) Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med 63:847–854
doi: 10.2967/jnumed.121.262398
pubmed: 34649942
pmcid: 9157724
Ferraro DA, Rüschoff JH, Muehlematter UJ et al (2020) Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with (68)Ga-PSMA-11-PET. Theranostics 10:6082–6094
doi: 10.7150/thno.44584
pubmed: 32483440
pmcid: 7255040
Yaxley JW, Raveenthiran S, Nouhaud FX et al (2019) Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int 124:401–407
doi: 10.1111/bju.14828
pubmed: 31141284
de Rooij M, Israël B, Tummers M et al (2020) ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur Radiol 30:5404–5416
doi: 10.1007/s00330-020-06929-z
pubmed: 32424596
pmcid: 7476997